Skip to main content
Caplight Logo









Perceive Pharma

Perceive Pharma

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttp://perceivepharma.com/

Last Round

Series A

Feb 18, 2025

Est. Valuation

$169M

Total Funding Raised

$15M

Company Overview

Perceive Pharma is a drug discovery company that is advancing novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

neuroprotective therapeuticssmall molecule drugsglaucoma treatmentophthalmologybiopharmaretinal neuroprotectionIOP-independent therapydrug discoverydrug developmentclinical stage pharmafirst-in-class drugpharma licensinggenomic screeninglife science incubator

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Perceive Pharma Comparables

Compare Perceive Pharma with similar companies based on industry and business-model similarity.

Perceive Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Perceive Bio
82%
Nura Bio
60%
Eli Lilly and Company
59%

Perceive Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 18, 2025
Series AAug 1, 2018

Perceive Pharma Investors

Notable investors and investment history

Perceive Pharma investors
InvestorRounds
Deerfield ManagementSeries A
GVSeries A
BraidwellSeries A
Catalio Capital ManagementSeries A
Johnson & Johnson Innovation - JJDCSeries A
Foundation Fighting BlindnessSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 18, 2025

    $15M round led by Deerfield Management

  • Aug 1, 2018

    Deerfield Management led the Series A round.

Perceive Pharma Filings

Explore SEC and related filing metadata, where available.

Perceive Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Perceive Pharma's valuation, stock price, and market status.

Is Perceive Pharma a public or private company?

Perceive Pharma is a private company.

What is the current stock price of Perceive Pharma?

Perceive Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is Perceive Pharma worth (valuation)?

Perceive Pharma's valuation is estimated at $169.0M based on funding round data.

Can I buy Perceive Pharma stock?

Perceive Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Perceive Pharma's last funding round?

Perceive Pharma's most recent funding round was Series A on February 18, 2025.

Who are the main investors in Perceive Pharma?

Key investors in Perceive Pharma include Deerfield Management.

Will Perceive Pharma IPO soon?

No public IPO plans have been announced for Perceive Pharma.

How can I track Perceive Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Perceive Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth San Francisco, California
Year Founded2025
Last FundingFeb 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?